• The technology described in this briefing is Optilume. It is used to treat anterior urethral strictures that need treating again because they have re-occurred after first-line endoscopic treatment.

  • The innovative aspects are that it incorporates balloon dilation with an anti-proliferative drug called paclitaxel, which is delivered around the inside surface of the urethra during the procedure.

  • The intended place in therapy would be as an alternative to standard care for urethral strictures.

  • The main points from the evidence summarised in this briefing are from 1 single-arm prospective study including a total of 53 men. It shows that Optilume is safe for treating urethral strictures, and early 2‑year efficacy results are encouraging.

  • Key uncertainties around the evidence or technology are that there are no comparative studies, the evidence has limited applicability to the NHS, and longer-term evidence is needed for Optilume, including the effect of paclitaxel on the tissues.

  • The cost of Optilume is £1,350 per unit (excluding VAT). The resource impact would be more than urethrotomy or dilation (£937) but less than urethroplasty (£4,300).